Free Trial

CytoDyn (OTCMKTS:CYDY) Share Price Passes Below 50-Day Moving Average - Time to Sell?

CytoDyn logo with Medical background

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report)'s share price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.24 and traded as low as $0.20. CytoDyn shares last traded at $0.20, with a volume of 1,025,437 shares changing hands.

CytoDyn Stock Down 5.1 %

The stock has a market cap of $264.97 million, a PE ratio of -21.50 and a beta of 1.33. The firm's fifty day moving average price is $0.24 and its 200 day moving average price is $0.18.

About CytoDyn

(Get Free Report)

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

Featured Stories

Should You Invest $1,000 in CytoDyn Right Now?

Before you consider CytoDyn, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.

While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy Early: 3 Tech Trends With Millionaire-Making Potential
SMCI Stumbles on Earnings: Why Some Investors Still Want In
5 Stocks to BUY NOW in May 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines